If FDA approves an IDE application, the sponsor may begin subject enrollment upon receipt of IRB approval and in accordance with the limits described in FDA's decision letter, including the maximum numbers of U.S. subjects and investigational sites. An IDE application is approved if FDA has determined that: the sponsor has provided sufficient data to support initiation of a human clinical study; no subject protection concerns preclude initiation of the investigation; and no additional conditions must be met.
In some cases, FDA may determine that an outstanding issue remains that can be addressed with data that will be gathered concurrently with the enrollment of a portion of study subjects (i.e., staged approval, see Section 5). FDA may also inform the sponsor of recommended modifications to the study design that FDA believes will improve the study and may be necessary to enable the study to support a future marketing application (i.e., study design considerations) as well as other issues that FDA believes should be considered in preparing for a marketing application or a future clinical investigation (i.e., future considerations). These types of feedback are discussed in Section 7 of this document.
If FDA approves an IDE application with conditions, the sponsor may begin subject enrollment upon,
Outstanding issues that may lead to approval with conditions include:
30 DAYS AFTER FDA's RECEIPT of AMENDMENT = Sponsor will be informed of FDA's decision. During this time, the sponsor may continue to conduct the study. If FDA determines that the issues have been adequately resolved, it will grant approval.
If any issues remain, FDA may again grant approval with conditions and will communicate those remaining outstanding issues to the sponsor by letter. In this case, the sponsor may continue to enroll subjects in the study provided that, within 45 days, the sponsor responds to the remaining issues identified in FDA's letter. If the sponsor's response to FDA's questions raises concerns regarding subject safety, or the sponsor does not respond, FDA may take appropriate regulatory actions to protect study subjects, including placing a clinical hold on the study. If the study is placed on hold, no additional subjects may be enrolled, and previously enrolled study subjects should receive appropriate monitoring and treatment for their safety.
If an IDE application is disapproved, the sponsor may not initiate enrollment in the clinical investigation until the sponsor submits an amendment to the IDE to respond to the deficiencies identified in FDA’s letter and subsequently receives a new letter from FDA granting approval or approval with conditions.
Consistent with 21 CFR 812.30(b) and section 520(g) of the FD&C Act, FDA may disapprove an IDE for any of the following reasons: